Allogeneic car-t platform using hla-matched bank of ipscs, and related compositions, systems, and methods

A method of manufacturing an induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor T cell (CAR-T) composition tailored for treatment of a particular subject or particular group of subjects, said method comprising the steps of:

• (a) storing, by a processor of a computing device, a database comprising a data entry corresponding to each of a plurality of characterized cells in a physical repository, wherein the characterized cells comprise iPSCs and/or iPSC-derived cells;
• (b) receiving, by the processor, a query from a user comprising an identification of a cell type of the particular subject or particular group of subjects;
• (c) matching, by the processor, the query to one or more data entries of the database, each of the matching data entries corresponding to each of the plurality of characterized cells having a cell type compatible with the particular subject or particular group of subjects, thereby identifying as compatible with the subject the one or more characterized cells;
• (d) retrieving, from a physical repository, compatible cells corresponding to the one or more characterized cells identified as compatible with the particular subject or particular group of subjects;
• and
• (e) producing the iPSC-derived CAR-T composition using the retrieved compatible cells.

A method of storing a iPSC-derived CAR-T composition tailored for treatment of a particular subject or particular group of subjects, said method comprising the steps of:

• (a) identifying, by a processor of a computing device, as compatible with the particular subject or particular group of subjects, one or more iPSC-derived CAR-T compositions derived using compatible cells corresponding to the one or more iPSCs and/or one or more iPSC-derived cells identified as compatible with the particular subject or particular group of subjects;
• (b) labelling, by a processor of a computing device, the one or more iPSC-derived CAR-T compositions with a label, wherein the label comprises information relating to the one or more iPSCs and/or one or more iPSC-derived cells, and a classification of the one or more iPSCs and/or one or more iPSC-derived cells the iPSC-derived CAR-T composition is derived from;
• and
• (c) storing, by a processor of a computing device, a database comprising a data entry corresponding to each label in a physical repository.

A method of retrieving one or more produced, labeled and stored iPSC-derived CAR-T compositions derived using iPSCs and/or iPSC-derived cells, said method comprising the steps of:

• (a) identifying, by a processor of a computing device, as compatible with a particular subject or particular group of subjects, one or more iPSC-derived CAR-T compositions derived using one or more iPSCs and/or iPSC-derived cells identified as compatible with the particular subject or particular group of subjects;
• (b) retrieving, from a physical repository, the one or more compatible iPSC-derived CAR-T compositions corresponding to the one or more iPSCs and/or one or more iPSC-derived cells identified as compatible with the particular subject or particular group of subjects;
• and
• (c) updating, by a processor of a computing device, a database comprising data entries corresponding to the particular subject or particular group of subjects.

A method of administering an iPSC-derived CAR-T composition tailored for treatment of a particular subject or particular group of subjects, said method comprising the steps of:

• (a) identifying, by a processor of a computing device, the particular subject or particular group of subjects, as having low lymphocyte numbers or poor lymphocyte quality;
• (b) identifying, by the processor, as compatible with the particular subject or particular group of subjects, one or more iPSCs and/or one or more iPSC-derived cells;
• (c) retrieving compatible cells corresponding to the one or more iPSCs and/or one or more iPSC-derived cells identified as compatible with the particular subject or particular group of subjects;
• (d) producing the iPSC-derived CAR-T composition using the retrieved compatible cells;
• and
• (e) administering to the particular subject or particular group of subjects the iPSC-derived CAR-T composition.